Ingredion's £2.7bn Tate & Lyle Bid Tests London's Mid-Cap Appeal

What Ingredion is offering, and the regulatory timetable

Tate & Lyle (LSE: TYLE) confirmed on Thursday that its board is in discussions with Ingredion (NYSE: INGR) over a possible offer at 615p per share, according to a company statement. The proposal values the London-listed firm at approximately £2.7bn.

Shares in Tate & Lyle jumped 45 per cent on the day to 543p, as reported by City AM. The stock had been trading at roughly 375p before the announcement, implying a premium of approximately 64 per cent at the proposed price.

The company's statement noted that the proposal "follows a number of earlier approaches from Ingredion to the Board regarding a possible offer for Tate & Lyle." It added that "there can be no certainty that any offer will be made, nor as to the final terms on which any offer might be made."

Under UK Takeover Panel rules, Ingredion has until 5pm on 11 June to formalise a firm bid or withdraw its approach, according to regulatory filings. That four-week window gives both boards limited time to agree terms, conduct due diligence and secure financing.

Ingredion, headquartered in Illinois, supplies starches, sweeteners and pea protein to the food, beverage, brewing and pharmaceutical industries. The company reported 2025 revenues of approximately $7.5bn. Its shares fell roughly two per cent on the US market open following the announcement, to around $103, leaving the stock down approximately five per cent year-to-date, according to City AM.

How Ingredion would finance a £2.7bn cash or mixed bid remains unclear. The company has not disclosed funding arrangements, and no formal offer document has been published.

How the CP Kelco deal reshaped Tate & Lyle's profile

The irony at the centre of this bid is that Tate & Lyle's own acquisition strategy may have made it a more attractive target.

In 2024, the company spent $1.8bn (£1.4bn) acquiring CP Kelco, a pectin and gum business, in what management described as a move to position Tate & Lyle as a "leader in mouthfeel [and] a critical driver of customer solutions," according to the company's announcement at the time.

The deal substantially broadened Tate & Lyle's texturants portfolio. Before CP Kelco, the firm was primarily known for starches and sweeteners. Afterwards, it held meaningful positions in pectin, gellan gum and other hydrocolloids used to modify texture in food and beverages. For a buyer like Ingredion, which already operates at scale in starches and sweeteners, the CP Kelco assets fill a gap that would have been difficult and expensive to build organically.

There is a pattern here that boards considering large acquisitions should study carefully. A mid-cap company that executes a deal to diversify its capabilities can simultaneously make itself more strategically coherent and more appealing to a larger rival. The very assets acquired to strengthen competitive positioning become the assets that attract a predator.

Tate & Lyle's corporate history underscores the long arc of this transformation. The company was created in 1921 through the merger of rival sugar refiners founded by Henry Tate and Abram Lyle, and has been listed in London since 1938, according to company records. In 2010, it sold its sugar refining business and the rights to its golden syrup brand to American Sugar Refining for £211m. The CP Kelco acquisition completed a decade-long pivot from commodity sugar to speciality ingredients.

A combined Ingredion and Tate & Lyle entity would create a formidable global supplier of starches, sweeteners, pectin and texture solutions, with combined revenues well in excess of $10bn. For supply-chain leaders in food and beverage, the consolidation would concentrate significant purchasing power in a single organisation.

London's mid-cap discount: why overseas buyers keep circling

The Tate & Lyle approach is not an isolated event. It arrives in the same week that FTSE 100 testing company Intertek said it was "minded" to accept a private takeover bid, and FTSE 250-listed Spire Healthcare saw its shares jump following a £1bn offer, as reported by City AM.

The pattern is now well established. Overseas acquirers, whether corporate or private equity, have repeatedly targeted London-listed companies at valuations that domestic investors have been unwilling to pay. The reasons are structural and well documented: lower liquidity in UK mid-cap stocks, persistent outflows from UK equity funds, and valuation multiples that trail US and European peers.

For a company like Ingredion, the arithmetic is straightforward. Tate & Lyle's pre-bid market capitalisation of roughly £1.9bn (based on the approximately 375p share price) represented a discount to the strategic value of its ingredient portfolio, particularly after the CP Kelco acquisition added high-margin texturant capabilities. A 64 per cent premium is substantial, but if the combined entity can extract meaningful synergies in procurement, manufacturing and distribution, the deal economics may still work for Ingredion's shareholders.

The broader concern for UK capital markets is what happens when a steady stream of mid-cap companies are acquired and delisted. Each departure reduces the depth and diversity of London's public markets, potentially making the remaining listed companies even more vulnerable to the same valuation discount that attracted buyers in the first place.

Scale of recent UK takeout activity

The Tate & Lyle bid joins a growing list of foreign and private equity approaches to UK public companies in recent months. The Intertek and Spire Healthcare situations this week alone represent billions of pounds in potential deal value. For operators and finance directors at UK-listed firms, the message is clear: boards that do not actively address valuation gaps risk having the decision made for them by an acquirer.

What boards can take from the bid dynamics

The Tate & Lyle situation offers several practical observations for boards weighing significant M&A.

First, acquisitions that enhance strategic coherence can attract unwanted attention. The CP Kelco deal made Tate & Lyle a more complete ingredients platform. It also made the company a neater fit for Ingredion's existing portfolio. Boards contemplating large deals should stress-test whether the resulting entity becomes a more obvious target, and whether that risk is acceptable.

Second, the regulatory timetable matters. The 11 June deadline imposed by the Takeover Panel creates a defined window within which the Tate & Lyle board must negotiate, assess alternatives and consult shareholders. That compressed timeline can favour a well-prepared bidder.

Third, the valuation context is critical. Tate & Lyle's shares were trading at roughly 375p before the approach, a level that reflected neither the full strategic value of the CP Kelco acquisition nor the company's improved margin profile. Whether the 615p offer adequately reflects that value is a question for the board and its advisers, not for outside commentary.

"The proposal follows a number of earlier approaches from Ingredion to the Board regarding a possible offer for Tate & Lyle."

That disclosure, from Tate & Lyle's own statement, suggests the conversation has been running for some time. It also implies that earlier approaches were at lower prices, and that the board held firm until the terms improved. The dynamics of that negotiation, once fully disclosed, may prove instructive for other mid-cap boards facing similar situations.

For now, the outcome remains uncertain. The 11 June deadline will determine whether this becomes a completed transaction or another approach that fell away. Either way, the Tate & Lyle bid is a sharp illustration of the forces reshaping UK public markets: overseas capital, domestic valuation discounts, and the unintended consequences of strategic ambition.